trans-4-tert-butylcyclohexylamine hydrochloride | 54572-02-0

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: trans-4-tert-butylcyclohexylamine hydrochloride
• CAS: 54572-02-0
• 化学式: C₁₀H₂₁N*ClH
• 分子量: 191.744
• InChiKey: GKZRLLGEYNJZDA-JUAUBFSOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.97
• 重原子数：
  12.0
• 可旋转键数：
  0.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.02
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  N-(2,4-dioxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-6-yl)acetamide 、 trans-4-tert-butylcyclohexylamine hydrochloride 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以49%的产率得到5-acetylamino-2-amino-N-(trans-4-tert-butylcyclohexyl)benzamide
  参考文献：
  名称：

  [EN] TREATMENT OF CHAGAS DISEASE
  [FR] TRAITEMENT DE LA MALADIE DE CHAGAS

  摘要：

  该发明提供了以下式的化合物：其中L1和L2分别选自O和S；R1为C3-C6直链或支链烷基，C3-C7环烷基，C5-C7环烯基，脱氢胆固醇，苯基或饱和杂环烷基，其中任一可选择地被取代；R2为H，甲基或乙基；R5为NRxCORy，NRxRy，CH2COCH3，CH2C≡N，或者是可选择地被取代的5-或6-成员杂芳基团；X、Y和Z分别为N或CH；Rx分别为H或C1-C4烷基；Ry分别为H，CrC4烷基，苯基或苄基，其中任一可选择地被取代；n为0-3；盐、水合物和N-氧化物，其中可选择的取代基在权利要求中进一步定义。这些化合物在预防或治疗锥虫病等锥虫病方面具有用途。

  公开号：

  WO2015189595A1

文献信息

• Urea Glucokinase Activators
  申请人：Lau Jesper

  公开号：US20090105482A1

  公开（公告）日：2009-04-23

  The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.

  本发明提供了一种具有一般式(I)的化合物，其中取代基在申请书中进一步定义，以及在所附的实施例中进一步描述的本发明的其他实施例。本发明还提供了使用该化合物制备药物治疗各种疾病的用途，例如治疗2型糖尿病。
• 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents
  申请人：Pfau Roland

  公开号：US20120115902A1

  公开（公告）日：2012-05-10

  There are provided compounds of formula (I), wherein R 1 , R 6 , R 8 , Q 2 , Q 3 , Q 3a , Q 4 , L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.

  提供了公式（I）的化合物，其中R1、R6、R8、Q2、Q3、Q3a、Q4、L和A的含义在说明中给出，并且其药学上可接受的盐，在希望和/或需要抑制MAPEG家族成员活性的疾病治疗中非常有用，特别是在炎症和/或癌症治疗中。
• Urea glucokinase activators
  申请人：NOVO NORDISK A/S

  公开号：EP2377856A1

  公开（公告）日：2011-10-19

  The invention provides a compound of general formula (1) wherein the substituents are defined futher in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.

  本发明提供了通式（1）的化合物 其中取代基在本申请中进一步定义，以及在所附实施例中描述的本发明的进一步实施例。 本发明还提供了本发明化合物用于制备治疗各种疾病的药物的用途，例如用于治疗 2 型糖尿病。
• Discovery and Optimization of a Compound Series Active against <i>Trypanosoma cruzi</i>, the Causative Agent of Chagas Disease
  作者：Justin R. Harrison、Sandipan Sarkar、Shahienaz Hampton、Jennifer Riley、Laste Stojanovski、Christer Sahlberg、Pia Appelqvist、Jessey Erath、Vinodhini Mathan、Ana Rodriguez、Marcel Kaiser、Dolores Gonzalez Pacanowska、Kevin D. Read、Nils Gunnar Johansson、Ian H. Gilbert

  DOI：10.1021/acs.jmedchem.9b01852

  日期：2020.3.26

  Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against T. cruzi. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series.
• UREA GLUCOKINASE ACTIVATORS
  申请人：Novo Nordisk A/S

  公开号：EP1904467A1

  公开（公告）日：2008-04-02